In Vitro Hollow-Fiber Studies Assessing Antibacterial Activity of Ceftolozane/Tazobactam Against Multidrug-Resistant Pseudomonas Aeruginosa | Zendy

Donna Carr | Zendy; Zufei Zhang | Zendy; Qian Si | Zendy; Fred Racine | Zendy; Jing Chen Xiao | Zendy; Ravi Katwaru | Zendy; Michael K. Wismer | Zendy; Matthew G. Johnson | Zendy; Hwa-ping Feng | Zendy; Katherine Young | Zendy; Matthew L. Rizk | Zendy; Mary Motyl | Zendy

Open Access

In Vitro Hollow-Fiber Studies Assessing Antibacterial Activity of Ceftolozane/Tazobactam Against Multidrug-Resistant Pseudomonas Aeruginosa

Author(s) -

Donna Carr,

Zufei Zhang,

Qian Si,

Fred Racine,

Jing Chen Xiao,

Ravi Katwaru,

Michael K. Wismer,

Matthew G. Johnson,

Hwa-ping Feng,

Katherine Young,

Matthew L. Rizk,

Mary Motyl

Publication year - 2020

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofaa469

Subject(s) - pseudomonas aeruginosa , medicine , microbiology and biotechnology , tazobactam , pneumonia , in vitro , antibiotics , bacteria , biology , imipenem , antibiotic resistance , biochemistry , genetics

Our hollow-fiber infection model simulated the projected steady-state pharmacokinetics of ceftolozane and tazobactam in lung epithelial lining fluid of patients with pneumonia receiving 3 g of ceftolozane/tazobactam every 8 hours. Results confirmed the previously established in vitro activity of ceftolozane/tazobactam at and above approved breakpoints against multidrug-resistant Pseudomonas aeruginosa, regardless of Pseudomonas-derived cephalosporinase allele.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research